also reported five patients with CNS lymphoma (one patient with PCNSL and four patients with secondary CNS lymphoma) who underwent anti-CD19 and CD22 cocktail CAR-T cell therapy with a follow-up of 6-16 months. The gene discussed is CD22; the disease is primary central nervous system lymphoma.